1.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-04, MAYO-977802
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IDEC-106-06, MAYO-987804, UCLA-9808026
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 307940/106-20, NCT00322218
|
|
4.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-9804024, IDEC-106-05, NCI-G99-1614
|
|
5.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI #03-005, NCT00177554
|
|
6.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 59
Sponsor: Other
Protocol IDs: 2007.462, NCT00498043
|
|
7.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: GELTAMO-LCM-04-02, 2005-004400-37, NCT00505232
|
|
8.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: HO04405, NCT00582166
|
|
9.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: DSHNHL 2004-R4, NCT00521560
|
|
10.
|
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 to 65
Sponsor: Other
Protocol IDs: CHUBX 2007/11, NCT00607854
|
|
11.
|
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067697, UAB-9930, IDEC-106-98, GUMC-00095, NCI-G00-1731, NCT00005592
|
Mobile | Español
